Class Actions vs. Merck, Schering Over Vytorin Get Judge's Go Ahead

, New Jersey Law Journal


A federal judge certifies as class actions a pair of suits claiming Merck & Co. and the former Schering-Plough Corporation withheld information about the effectiveness of the anticholesterol drug Vytorin.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Continue to Lexis Advance®

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at

What's being said

  • LulaineRDLegalFunding

    This is a big step for the plaintiffs in what may be a really long case against a huge company like Merck. The accusations in this case show that this is going to be a long case but the problem is there could a precedent set with the outcome of the case.

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202572954677

Thank you!

This article's comments will be reviewed.